Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ATOS
$4.23
$
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Next Earnings
2026-02-25
Beta
1.336
Average Volume
Market Cap
Last Dividend
CIK
0001488039
ISIN
US04962H7044
CUSIP
04962H704
CEO
Steven C. Quay
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
15
IPO Date
2012-11-08
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus PT from Analysts | Shares of Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) have earned a consensus recommendation of "Hold" from the five research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation | Defense World | 2026-02-20 01:33:17 |
| Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 29.7% in January | Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 4,696,759 shares, a growth of 29.7% from the January 15th total of 3,621,023 shares. Approximately 60.2% of the shares of the stock are sold short. Based | Defense World | 2026-02-16 02:15:04 |
| Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook | SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. | PRNewsWire | 2026-02-11 08:30:00 |
| Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program | Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today reaffirmed its strong market position around its Duchenne Muscular Dystrophy (DMD) program following yesterday's congressional announcement that it had passed a five-year reauthorization of the Rare Pediatric Disease Priority Review Voucher ("PRV") Program. The program extends the Company's ability to be eligible to receive a future PRV upon the U.S. Food and Drug Administration's ("FDA") approval following the FDA granting Rare Pediatric Disease ("RPD") designation to (Z)-endoxifen for the treatment of DMD late last year. | PRNewsWire | 2026-02-05 08:30:00 |
| Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd | Atossa Genetics Inc. (NASDAQ: ATOS)'s stock is scheduled to reverse split before the market opens on Monday, February 2nd. The 1-15 reverse split was announced on Monday, January 26th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 30th. Atossa Genetics Trading Down 10.0% Shares | Defense World | 2026-01-29 01:08:48 |
| Atossa Genetics Inc. (NASDAQ:ATOS) Receives $6.33 Consensus PT from Brokerages | Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) has received a consensus recommendation of "Hold" from the five brokerages that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average | Defense World | 2026-01-26 01:00:44 |
| Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 | Recognized for Visionary Leadership and Advancing Innovative Therapies in Oncology and Healthcare Technology SEATTLE, Jan. 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, announces that Founder, Chairman, President, and Chief Executive Officer Steven Quay, M.D., Ph.D. has been selected as one of "The Top 50 Healthcare Technology CEOs of 2025" by The Healthcare Technology Report. | PRNewsWire | 2026-01-21 09:05:00 |
| Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy | Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE, Jan. 16, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that the U.S. Food and Drug Administration ("FDA") Office of Orphan Products Development ("OOPD") has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy ("DMD"). "In addition to the previously received Rare Pediatric Disease designation, Orphan Drug Designation for (Z)-endoxifen in Duchenne muscular dystrophy is an important milestone for Atossa as we move forward developing (Z)-endoxifen for this serious and debilitating disease," noted Steven C. | PRNewsWire | 2026-01-16 16:40:00 |
| Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer | SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") issued a "Study May Proceed" letter for the Company's study in metastatic breast cancer which was the subject of a recent investigational new drug application for (Z)-endoxifen. "This letter marks an important regulatory milestone for Atossa and to potentially expand the use of (Z)-endoxifen for metastatic ER+/HER2- Breast Cancer. | PRNewsWire | 2026-01-06 08:15:00 |
| Reviewing Atossa Genetics (NASDAQ:ATOS) and Autonomix Medical (NASDAQ:AMIX) | Autonomix Medical (NASDAQ: AMIX - Get Free Report) and Atossa Genetics (NASDAQ: ATOS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends. Insider and Institutional Ownership 10.8% of Autonomix | Defense World | 2026-01-04 01:55:02 |
| Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest | Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) saw a large growth in short interest in December. As of December 15th, there was short interest totaling 2,284,050 shares, a growth of 47.0% from the November 30th total of 1,554,063 shares. Currently, 1.9% of the shares of the stock are short sold. Based on an average | Defense World | 2025-12-29 05:54:56 |
| Atossa Genetics (NASDAQ:ATOS) & IDEXX Laboratories (NASDAQ:IDXX) Head-To-Head Survey | IDEXX Laboratories (NASDAQ: IDXX - Get Free Report) and Atossa Genetics (NASDAQ: ATOS - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership. Profitability This table compares IDEXX Laboratories and Atossa | Defense World | 2025-12-22 01:12:45 |
| Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category | Recognized for Advancing (Z)-Endoxifen, a Precision-Engineered Endocrine Therapy with Potential Across Multiple Breast Cancer and Rare Disease Settings SEATTLE , Dec. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, announces that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards. The Company was honored with the Research and Development Award in the Precision Endocrine Therapy category. | PRNewsWire | 2025-12-17 08:15:00 |
| Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened | Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.85 and traded as low as $0.70. Atossa Genetics shares last traded at $0.7147, with a volume of 2,877,072 shares traded. Analysts Set New Price Targets Several equities | Defense World | 2025-12-16 05:31:01 |
| Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium | Studies highlight findings regarding the potential use of (Z)-endoxifen to advance breast cancer treatment and risk reduction SEATTLE , Dec. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of high unmet need, presented four clinical trial updates on (Z)-endoxifen at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025, in San Antonio, TX. "Clinical trial updates and data presented at SABCS 2025 reinforce our focus on the therapeutic value of (Z)-endoxifen across the breast care continuum," said Steven Quay, M.D. | PRNewsWire | 2025-12-15 08:00:00 |
| Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy | Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval SEATTLE , Dec. 11, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy ("DMD"). RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. | PRNewsWire | 2025-12-11 08:00:00 |
| Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen | New patent further strengthens global intellectual property estate supporting Atossa's lead program across the breast cancer spectrum and other hormone-driven conditions SEATTLE , Dec. 9, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies in areas of significant unmet need in breast cancer, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,479,790 B2, titled, "Methods for Making and Using Endoxifen. | PRNewsWire | 2025-12-09 08:00:00 |
| Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum | Company positioned to pursue expedited regulatory pathways in metastatic, neoadjuvant, and risk-reduction settings SEATTLE , Dec. 4, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment and prevention, announced the completion of a Type C meeting with the U.S. Food and Drug Administration ("FDA") on November 17, 2025, to review regulatory strategy for advancing (Z)-endoxifen. During the meeting, the FDA provided the Company feedback on potential expedited regulatory pathways and development options across metastatic disease, neoadjuvant treatment, and breast cancer risk-reduction settings. | PRNewsWire | 2025-12-04 08:00:00 |
| Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma | CAMBRIDGE, Mass. , Dec. 2, 2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa") (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel treatments for breast cancer and other serious conditions, announce the publication of a joint study evaluating the potential of (Z)-endoxifen for glioblastoma multiforme (GBM). | PRNewsWire | 2025-12-02 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-20 | 2026-02-20 | View Filing |
| 424B5 | 2026-02-20 | 2026-02-20 | View Filing |
| 424B3 | 2026-02-20 | 2026-02-20 | View Filing |
| 8-K | 2026-02-17 | 2026-02-17 | View Filing |
| 8-K | 2026-02-11 | 2026-02-11 | View Filing |
| 4/A | 2026-01-30 | 2026-01-30 | View Filing |
| 8-K | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-22 | 2026-01-22 | View Filing |
| 8-K | 2026-01-09 | 2026-01-09 | View Filing |
| 8-K | 2026-01-06 | 2026-01-06 | View Filing |
| DEF 14A | 2025-12-22 | 2025-12-22 | View Filing |
| PRE 14A | 2025-12-12 | 2025-12-12 | View Filing |
| 8-K | 2025-12-04 | 2025-12-04 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-10-21 | 2025-10-21 | View Filing |
| 3 | 2025-10-21 | 2025-10-21 | View Filing |
| 8-K | 2025-10-14 | 2025-10-14 | View Filing |
| 8-K | 2025-09-26 | 2025-09-26 | View Filing |
| 8-K | 2025-09-08 | 2025-09-08 | View Filing |
| 8-K | 2025-08-21 | 2025-08-21 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| SC 13G/A | 2025-07-29 | 2025-07-29 | View Filing |
| SC 13G/A | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-12 | 2025-05-09 | View Filing |
| 8-K | 2025-04-07 | 2025-04-07 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| ARS | 2025-03-26 | 2025-03-26 | View Filing |
| DEF 14A | 2025-03-26 | 2025-03-26 | View Filing |
| S-8 | 2025-03-26 | 2025-03-26 | View Filing |
| 10-K | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-12 | 2025-03-12 | View Filing |
| 8-K | 2025-02-24 | 2025-02-24 | View Filing |
| SC 13G/A | 2025-02-07 | 2025-02-07 | View Filing |
| 8-K | 2025-02-04 | 2025-02-04 | View Filing |
| 8-K | 2024-12-10 | 2024-12-10 | View Filing |
| 8-K | 2024-11-19 | 2024-11-19 | View Filing |
| 424B5 | 2024-11-19 | 2024-11-19 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G/A | 2024-11-04 | 2024-11-04 | View Filing |
| 8-K | 2024-11-04 | 2024-11-04 | View Filing |
| SC 13G | 2024-10-22 | 2024-10-22 | View Filing |
| 10-Q | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-07-02 | 2024-07-02 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| EFFECT | 2024-05-24 | 2024-05-24 | View Filing |
| DEF 14A | 2024-05-23 | 2024-05-23 | View Filing |
| DEL AM | 2024-05-14 | 2024-05-14 | View Filing |
| S-3 | 2024-05-13 | 2024-05-13 | View Filing |
| 10-Q | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-05-13 | 2024-05-13 | View Filing |
| ARS | 2024-05-10 | 2024-05-10 | View Filing |
| PRE 14A | 2024-05-10 | 2024-05-10 | View Filing |
| 4 | 2024-04-11 | 2024-04-11 | View Filing |
| 8-K/A | 2024-04-02 | 2024-04-01 | View Filing |
| 10-K | 2024-04-01 | 2024-04-01 | View Filing |
| 8-K | 2024-04-01 | 2024-04-01 | View Filing |
| 8-K | 2024-03-18 | 2024-03-18 | View Filing |
| 4 | 2024-03-14 | 2024-03-14 | View Filing |
| 3 | 2024-03-14 | 2024-03-14 | View Filing |
| 8-K | 2024-03-12 | 2024-03-12 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Neural Forcast | 81.89% | 1 | 837 | 0.04 | 0.09 | 95.67 |
| Volume Weighted Momentum Strategy | 35.35% | 0.73 | 4 | 0.09 | 0.29 | 49.12 |
| Williams PercentR Strategy | 13.97% | 1 | 370 | 0.01 | 0.04 | 27.74 |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |